Plasma Soluble Urokinase Plasminogen Activator Receptor and Behçet's Disease .
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04105439|
Recruitment Status : Not yet recruiting
First Posted : September 26, 2019
Last Update Posted : March 27, 2020
|Condition or disease|
Behçet's disease (BD) is a chronic, systemic vasculitis disease that can be evident in many systems and characterized by recurrent attacks, oral and/or genital aphthous ulcers, skin lesions, and inflammatory ocular findings. It was first described in 1937 by the Turkish dermatologist Hulusi Behçet.[1-3]
Although with an unclear pathogenesis, BD is considered a type of vasculitis triggered by immunological mechanisms. Increased levels of pro-inflammatory cytokines are reported in patients with BD. In the afflicted organs, a remarkable infiltration of neutrophils and lymphocytes can be seen.[4-6]
Diagnosis of BD is mainly clinical, on the association of symptoms, but diagnosis/classification criteria may help. Various sets of criteria were created for BD diagnosis and the recent one is the international criteria for Behçet's disease (ICBD) that was created by 27 countries in 2006 and revised in2014.
There is no standard laboratory marker for the diagnosis and follow-up of BD. certain cytokines and increased serum levels of C-reactive protein (CRP) are considered as markers of disease activity. Soluble urokinase plasminogen activator receptor (suPAR), a potential new biomarker, is a soluble form of the membrane-bound receptors expressed from and comprising mainly of various immune cells (monocytes, neutrophils, activated T lymphocytes, macrophages, endothelial cells, keratinocytes, smooth muscle cells and even tumor cells.  Numerous studies on various inflammatory diseases, cancer, tuberculosis, central nervous system infections, sepsis, liver fibrosis and inflammatory bowel disease have shown increased systemic levels of suPAR. In these diseases, suPAR systemic levels are shown to have a prognostic value in determining disease severity.
|Study Type :||Observational|
|Estimated Enrollment :||90 participants|
|Official Title:||Relation Between Plasma Soluble Urokinase Plasminogen Activator Receptor and Behçet's Disease .|
|Estimated Study Start Date :||May 1, 2020|
|Estimated Primary Completion Date :||November 1, 2021|
|Estimated Study Completion Date :||December 1, 2021|
healthy subjects who do not have the disease
patients with Behçet's disease
subjects who do have the disease ( Behçet's disease )
- evaluation of the level of suPAR in the study subjects. [ Time Frame: baseline ]to study the relation between leve of the marker and presence of the diesase.
- evaluation of the levels of suPAR with the activity of the disease. [ Time Frame: baseline ]to study relation between level of the marker and activity of the disease
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04105439
|Contact: Mohamed Farghaly Ramadan, MDemail@example.com|